ClinicalTrials.gg
CompletedNCT01535261CRYSTALUpdated Oct 27, 2016Results posted

Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

A Phase 3 interventional study of Ranibizumab 0.5 mg/0.05 ml in Macular Edema and Central Retinal Vein Occlusion, sponsored by Novartis Pharmaceuticals. Completed at 78 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-27.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
357
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 91 studies testing ranibizumab in Macular Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Macular Edema.

Enrollment
11th of 91
357 · median 50
Started
2012
with 7 others
Phase 3
25 of 91
none open now
Registered
38th of 91
by date
Lead sponsor
21 of 91
Novartis Pharmaceuticals

Among the 91 studies testing ranibizumab in Macular Edema, this one is the 11th largest by enrollment, is one of 8 that started in 2012, is one of 25 in phase 3, and was the 38th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

None of the 91 studies testing ranibizumab in Macular Edema is open now. The open studies under Macular Edema, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 91 studies testing ranibizumab in Macular Edema as a file.
02

Study summary

The present study provided additional efficacy and safety data for 0.5-mg ranibizumab using as needed (PRN) dosing over 24 months in patients with visual impairment due to macular edema secondary to Central Retinal Vein Occlusion (CRVO). Spectral domain high-definition optical coherence tomography (OCT) images was analyzed to gain insights into predictive factors for disease progression and the possibility of reduced monitoring was assessed in Year 2. The results of this open-label study provided long-term safety and efficacy data to further guide recommendations on the use of ranibizumab in this indication.

03

Conditions studied

  • Macular Edema
  • Central Retinal Vein Occlusion

Keywords

  • Ophthalmology
  • Ranibizumab
  • Central Retinal Vein Occlusion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients ≥ 18 years of age
  • Diagnosis of visual impairment exclusively due to ME secondary to CRVO
  • BCVA score at Screening and Baseline between 73 and 19 letters Early Treatment Diabetic Retinopathy Study (ETDRS), inclusively (approximate Snellen chart equivalent of 20/40 and 20/400)

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled blood pressure defined as systolic value of > 160 mm Hg or diastolic value of > 100 mm Hg at Screening or Baseline.
  • Any active periocular or ocular infection or inflammation at Screening or Baseline in either eye
  • Uncontrolled glaucoma at Screening or Baseline or diagnosed within 6 months before Baseline in either eye
  • Use of any systemic antivascular endothelial growth factor (anti-VEGF) drugs within 6 months before Baseline (eg, sorafenib [Nexavar®], sunitinib [Sutent®], bevacizumab [Avastin®])
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
357 participants (actual)

Study arms

  • Experimental
    Ranibizumab arm

    Intravitreal injection with standard dose of 0.5 mg/0.05mL PRN

    Drug: Ranibizumab 0.5 mg/0.05 ml

Interventions

  • DrugRanibizumab 0.5 mg/0.05 ml

    Drug page: Ranibizumab

    Patients will receive the first dose at Baseline, as an intravitreal injection with a standard dose of 0.5 mg/0.05 ml. Patients will receive at least 3 study treatments at monthly intervals (Day 1, Month 1 and Month 2). The last mandatory dose during treatment initiation will be administered approximately 60 days after the first study treatment. If there is no improvement in VA over the course of the first 3 injections, continued treatment is not recommended and the patient may receive alternative treatment at the investigator's discretion.

06

What researchers measure

Primary outcomes

  1. Mean Change in Best Corrected Visual Acuity (BCVA) at Month 12 Compared to Baseline

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. A positive average change from baseline of BCVA indicates improvement

    Time frame: Baseline to month 12

Secondary outcomes

  1. Mean Change in Best Corrected Visual Acuity (BCVA) at Month 24 Compared to Baseline

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. A positive average change from baseline of BCVA indicates improvement

    Time frame: Baseline to Month 24

  2. Mean Average Change in Best Corrected Visual Acuity (BCVA From Baseline Month 12 and Month 24

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. Mean Average Change: for each patient, first average change is calculated as the average of the changes from baseline to Month 1 over Month 12 (or Month 24). Then, mean average change is calculated as the average of average changes across all patients.

    Time frame: Baseline and Month 1 to 12 or Month 24

  3. Mean Average Change in BCVA From First Treatment Interruption (Due to BCVA Stabilization) to Month 12 and Month 24

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. Stability in visual acuity after treatment interruption indicates longer duration of the drug efficacy

    Time frame: Month 12 and Month 24

  4. Number of Patients With a BCVA Improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 Letters From Baseline to Month 12 and Month 24 in the Study Eye

    BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An increased score indicates improvement in acuity. This outcome assessed the number of participants who had improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 letters of visual acuity at month 12 as compared with baseline

    Time frame: Month 12 and Month 24

  5. Number of Patients With a BCVA Value of ≥ 73 Letters (Approximate 20/40 Snellen Chart Equivalent) at Month 12 and Month 24

    Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and month 12 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at month 12 and month 24 indicates a positive outcome.

    Time frame: Month 12 and Month 24

  6. Mean Change in Central Reading Center (CRC)-Assessed Central Subfield Thickness (CSFT) From Month 12 and Month 24 Compared to Baseline

    Retinal thickness was measured using Optical Coherence Tomography (OCT). The images were reviewed by a central reading center to ensure a standardized evaluation

    Time frame: Baseline, Month 12 and Month 24

  7. Mean Change in Patient-reported Outcomes in NEI-VFQ-25 Composite and Subscale Scores at Month 12 and Month 24 Compared to Baseline

    The survey consists of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranges from 0 (worst) to 100 which indicates the best possible response. The composite score and score of each of each construct also range from 0 to 100 as they are calculated as total scores divided by the number of questions. The higher the values of total scores represent better outcome. Scores per visit and of the change descriptively by visit.

    Time frame: Month 12 and Month 24

07

Results

Posted Jun 3, 2016

Participant flow

Participant flow — Overall Study
MilestoneRanibizumab Arm
Started357
Completed307
Not completed50
Withdrew: Physician decision8
Withdrew: Protocol violation3
Withdrew: Death5
Withdrew: Lost to follow-up8
Withdrew: Withdrawal by subject14
Withdrew: Adverse event12

Outcome measures

PrimaryMean Change in Best Corrected Visual Acuity (BCVA) at Month 12 Compared to Baseline

Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. A positive average change from baseline of BCVA indicates improvement

Time frame:
Baseline to month 12
Reported as:
Mean · Letters
Mean Change in Best Corrected Visual Acuity (BCVA) at Month 12 Compared to Baseline
LettersRanibizumab Arm
Mean Change in Best Corrected Visual Acuity (BCVA) at Month 12 Compared to Baseline12.3 ± 16.72
SecondaryMean Change in Best Corrected Visual Acuity (BCVA) at Month 24 Compared to Baseline

Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. A positive average change from baseline of BCVA indicates improvement

Time frame:
Baseline to Month 24
Reported as:
Mean · Letters
Mean Change in Best Corrected Visual Acuity (BCVA) at Month 24 Compared to Baseline
LettersRanibizumab Arm
Mean Change in Best Corrected Visual Acuity (BCVA) at Month 24 Compared to Baseline12.1 ± 18.60
SecondaryMean Average Change in Best Corrected Visual Acuity (BCVA From Baseline Month 12 and Month 24

Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. Mean Average Change: for each patient, first average change is calculated as the average of the changes from baseline to Month 1 over Month 12 (or Month 24). Then, mean average change is calculated as the average of average changes across all patients.

Time frame:
Baseline and Month 1 to 12 or Month 24
Reported as:
Mean · letters
Mean Average Change in Best Corrected Visual Acuity (BCVA From Baseline Month 12 and Month 24
lettersRanibizumab Arm
Month 1211.8 ± 12.44
Month 2412.1 ± 14.20
SecondaryMean Average Change in BCVA From First Treatment Interruption (Due to BCVA Stabilization) to Month 12 and Month 24

Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. Stability in visual acuity after treatment interruption indicates longer duration of the drug efficacy

Time frame:
Month 12 and Month 24
Reported as:
Mean · Letters
Mean Average Change in BCVA From First Treatment Interruption (Due to BCVA Stabilization) to Month 12 and Month 24
LettersRanibizumab Arm
Month 12 (n=310)-2.7 ± 8.04
Month 24 (n=331)-2.5 ± 8.95
SecondaryNumber of Patients With a BCVA Improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 Letters From Baseline to Month 12 and Month 24 in the Study Eye

BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An increased score indicates improvement in acuity. This outcome assessed the number of participants who had improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 letters of visual acuity at month 12 as compared with baseline

Time frame:
Month 12 and Month 24
Reported as:
Number · Letters
Number of Patients With a BCVA Improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 Letters From Baseline to Month 12 and Month 24 in the Study Eye
LettersRanibizumab Arm
BCVA improvement of >= 1 (Month 12)296
BCVA improvement of >= 5 (Month 12)275
BCVA improvement of >= 10 (Month 12)227
BCVA improvement of >= 15 (Month 12)175
BCVA improvement of >= 30 (Month 12)32
BCVA improvement of >= 1 (Month 24)290
BCVA improvement of >= 5 (Month 24)265
BCVA improvement of >= 10 (Month 24)224
BCVA improvement of >= 15 (Month 24)175
BCVA improvement of >= 30 (Month 24)44
SecondaryNumber of Patients With a BCVA Value of ≥ 73 Letters (Approximate 20/40 Snellen Chart Equivalent) at Month 12 and Month 24

Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and month 12 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at month 12 and month 24 indicates a positive outcome.

Time frame:
Month 12 and Month 24
Reported as:
Number · Letters
Number of Patients With a BCVA Value of ≥ 73 Letters (Approximate 20/40 Snellen Chart Equivalent) at Month 12 and Month 24
LettersRanibizumab Arm
Month 12169
Month 24161
SecondaryMean Change in Central Reading Center (CRC)-Assessed Central Subfield Thickness (CSFT) From Month 12 and Month 24 Compared to Baseline

Retinal thickness was measured using Optical Coherence Tomography (OCT). The images were reviewed by a central reading center to ensure a standardized evaluation

Time frame:
Baseline, Month 12 and Month 24
Reported as:
Mean · Microns
Mean Change in Central Reading Center (CRC)-Assessed Central Subfield Thickness (CSFT) From Month 12 and Month 24 Compared to Baseline
MicronsRanibizumab Arm
Change from Baseline at Month 12-335.7 ± 285.02
Change from Baseline at Month 24-349.1 ± 275.35
SecondaryMean Change in Patient-reported Outcomes in NEI-VFQ-25 Composite and Subscale Scores at Month 12 and Month 24 Compared to Baseline

The survey consists of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranges from 0 (worst) to 100 which indicates the best possible response. The composite score and score of each of each construct also range from 0 to 100 as they are calculated as total scores divided by the number of questions. The higher the values of total scores represent better outcome. Scores per visit and of the change descriptively by visit.

Time frame:
Month 12 and Month 24
Reported as:
Mean · Score on a scale
Mean Change in Patient-reported Outcomes in NEI-VFQ-25 Composite and Subscale Scores at Month 12 and Month 24 Compared to Baseline
Score on a scaleRanibizumab Arm
Change from baseline at Month 126.9 ± 12.65
Change from baseline at Month 246.6 ± 14.03

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab 0.5mg—64/357 (17.9%)244/357 (68.3%)
Most frequent serious events
Showing 10 of 92
Most frequent serious events
EventRanibizumab 0.5mg
Atrial fibrillationCardiac disorders3/357
Cardiac failureCardiac disorders3/357
Cardiac failure congestiveCardiac disorders3/357
Myocardial infarctionCardiac disorders3/357
Lower respiratory tract infectionInfections and infestations3/357
PneumoniaInfections and infestations3/357
Glaucoma (Study eye)Eye disorders2/357
Retinal ischaemia (Study eye)Eye disorders2/357
Visual acuity reduced (Study eye)Eye disorders2/357
Pancreatitis acuteGastrointestinal disorders2/357
Most frequent other events
Showing 10 of 42
Most frequent other events
EventRanibizumab 0.5mg
Intraocular pressure increased (Study eye)Investigations43/357
HypertensionVascular disorders40/357
NasopharyngitisInfections and infestations39/357
Ocular hypertension (Study eye)Eye disorders26/357
Eye pain (Study eye)Eye disorders25/357
Conjunctival haemorrhage (Study eye)Eye disorders24/357
Dry eye (Study eye)Eye disorders22/357
Visual acuity reduced (Study eye)Eye disorders21/357
HeadacheNervous system disorders21/357
Dry eye (Fellow untreated eye)Eye disorders19/357

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Ranibizumab Arm
Mean65.5 ± 12.68
Sex: Female, Male
Sex: Female, Male(Participants)Ranibizumab Arm
Female128
Male229
08

Study locations

78 sites
  • Novartis Investigative Site
    Parramatta, New South Wales 2150, Australia
  • Novartis Investigative Site
    Sydney, New South Wales 2000, Australia
  • Novartis Investigative Site
    Melbourne, Victoria 3002, Australia
  • Novartis Investigative Site
    Nedlands, Western Australia 6009, Australia
  • Novartis Investigative Site
    Linz, 4021, Austria
  • Novartis Investigative Site
    Wien, 1090, Austria
  • Novartis Investigative Site
    Calgary, Alberta T2H0C8, Canada
  • Novartis Investigative Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Novartis Investigative Site
    Victoria, British Columbia V8V 4X3, Canada
  • Novartis Investigative Site
    London, Ontario N6A 4G5, Canada
  • Novartis Investigative Site
    Boisbriand, Quebec J7H 1S6, Canada
  • Novartis Investigative Site
    Montreal, Quebec H1T 2M4, Canada
  • Novartis Investigative Site
    Olomouc, 775 20, Czech Republic
  • Novartis Investigative Site
    Praha 10, 100 34, Czech Republic
  • Novartis Investigative Site
    Glostrup, DK-2600, Denmark
  • Novartis Investigative Site
    Athens, GR 124 62, Greece
  • Novartis Investigative Site
    Heraklion Crete, GR 711 10, Greece
  • Novartis Investigative Site
    Larissa, GR 411 10, Greece
  • Novartis Investigative Site
    Thessaloniki, GR 546 29, Greece
  • Novartis Investigative Site
    Patras, 26504, Greece
  • Novartis Investigative Site
    Thessaloniki, GR 54636, Greece
  • Novartis Investigative Site
    Budapest, 1133, Hungary
  • Novartis Investigative Site
    Budapest, H-1083, Hungary
  • Novartis Investigative Site
    Debrecen, 4032, Hungary
  • Novartis Investigative Site
    Dublin 7, Ireland
  • Novartis Investigative Site
    Dublin, Ireland
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Firenze, FI 50134, Italy
  • Novartis Investigative Site
    Milano, MI 20100, Italy
  • Novartis Investigative Site
    Milano, MI 20132, Italy
  • Novartis Investigative Site
    Roma, RM 00144, Italy
  • Novartis Investigative Site
    Torino, TO 10122, Italy
  • Novartis Investigative Site
    Udine, 33100, Italy
  • Novartis Investigative Site
    Amsterdam, 1081, Netherlands
  • Novartis Investigative Site
    Leiden 2333 ZA, 2333, Netherlands
  • Novartis Investigative Site
    Nijmegen, 6525 GA, Netherlands
  • Novartis Investigative Site
    Rotterdam, 3011 BH, Netherlands
  • Novartis Investigative Site
    Tilburg, 5022 GC, Netherlands
  • Novartis Investigative Site
    Bielsko-Biala, 43-300, Poland
  • Novartis Investigative Site
    Gdansk, 80-809, Poland
  • Novartis Investigative Site
    Kraków, 31-501, Poland
  • Novartis Investigative Site
    Lublin, 20-079, Poland
  • Novartis Investigative Site
    Warszawa, 02-005, Poland
  • Novartis Investigative Site
    Wroclaw, 50-556, Poland
  • Novartis Investigative Site
    Coimbra, 3000-354, Portugal
  • Novartis Investigative Site
    Coimbra, 3030-163, Portugal
  • Novartis Investigative Site
    Lisboa, 1050-085, Portugal
  • Novartis Investigative Site
    Lisboa, 1349-019, Portugal
  • Novartis Investigative Site
    Porto, 4099-001, Portugal
  • Novartis Investigative Site
    Porto, 4200-319, Portugal
  • Novartis Investigative Site
    Zilina, Slovak Republic 010 01, Slovakia
  • Novartis Investigative Site
    Banska Bystrica, 975 17, Slovakia
  • Novartis Investigative Site
    Bratislava, 826 06, Slovakia
  • Novartis Investigative Site
    Valladolid, Castilla y Leon 47011, Spain
  • Novartis Investigative Site
    Barcelona, Cataluña 08022, Spain
  • Novartis Investigative Site
    Barcelona, Cataluña, Spain
  • Novartis Investigative Site
    L´Hospitalet de Llobregat, Cataluña 08907, Spain
  • Novartis Investigative Site
    Alicante, Comunidad Valenciana 03016, Spain
  • Novartis Investigative Site
    Valencia, Comunidad Valenciana 46014, Spain
  • Novartis Investigative Site
    Valencia, Comunidad Valenciana 46015, Spain
  • Novartis Investigative Site
    Santiago de Compostela, Galicia 15706, Spain
  • Novartis Investigative Site
    Bilbao, Pais Vasco 48006, Spain
  • Novartis Investigative Site
    Örebro, 701 85, Sweden
  • Novartis Investigative Site
    Bern, 3012, Switzerland
  • Novartis Investigative Site
    Lausanne, 1007, Switzerland
  • Novartis Investigative Site
    Zuerich, 8063, Switzerland
  • Novartis Investigative Site
    Ankara, 06100, Turkey
  • Novartis Investigative Site
    Frimley, Surrey GU16 7UJ, United Kingdom
  • Novartis Investigative Site
    Belfast, BT12 6BA, United Kingdom
  • Novartis Investigative Site
    Birmingham, B9 5SS, United Kingdom
  • Novartis Investigative Site
    Bristol, BS1 2LX, United Kingdom
  • Novartis Investigative Site
    Hull, HU3 2JZ, United Kingdom
  • Novartis Investigative Site
    Liverpool, L69 3GA, United Kingdom
  • Novartis Investigative Site
    London, EC1V 2PD, United Kingdom
  • Novartis Investigative Site
    London, NW1 5QH, United Kingdom
  • Novartis Investigative Site
    Newcastle upon Tyne, NE1 4LP, United Kingdom
  • Novartis Investigative Site
    Plymouth, PL4 6PL, United Kingdom
  • Novartis Investigative Site
    Southampton, SO16 6YD, United Kingdom
09

References and documents

Publications

  • Pawloff M, Bogunovic H, Gruber A, Michl M, Riedl S, Schmidt-Erfurth U. SYSTEMATIC CORRELATION OF CENTRAL SUBFIELD THICKNESS WITH RETINAL FLUID VOLUMES QUANTIFIED BY DEEP LEARNING IN THE MAJOR EXUDATIVE MACULAR DISEASES. Retina. 2022 May 1;42(5):831-841. doi: 10.1097/IAE.0000000000003385. PubMed 34934034 ↗
  • Larsen M, Waldstein SM, Priglinger S, Hykin P, Barnes E, Gekkieva M, Das Gupta A, Wenzel A, Mones J; CRYSTAL Study Group. Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL Study. Ophthalmol Retina. 2018 Feb;2(2):134-142. doi: 10.1016/j.oret.2017.05.016. Epub 2017 Sep 9. PubMed 31047340 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2016, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2012
First posted
Feb 17, 2012
Start
Feb 2012
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Results first posted
Jun 3, 2016
Last update
Oct 27, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01535261
Responsible party
Sponsor
First posted
Feb 17, 2012
Start date
Feb 2012
Primary completion
Mar 2015
Completion
Mar 2015
Results posted
Jun 3, 2016
Last update
Oct 27, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion